Benitec Biopharma Limited (BNTC) Upgraded to Hold at ValuEngine
ValuEngine upgraded shares of Benitec Biopharma Limited (NASDAQ:BNTC) from a sell rating to a hold rating in a research report report published on Friday.
Separately, Maxim Group restated a hold rating on shares of Benitec Biopharma Limited in a report on Wednesday, August 30th.
Shares of Benitec Biopharma Limited (NASDAQ:BNTC) traded up 0.95% during mid-day trading on Friday, reaching $2.13. The company had a trading volume of 14,534 shares. The company’s market capitalization is $21.85 million. Benitec Biopharma Limited has a 12 month low of $1.30 and a 12 month high of $5.48. The firm’s 50-day moving average is $2.08 and its 200 day moving average is $2.33.
COPYRIGHT VIOLATION NOTICE: This piece of content was originally posted by Daily Political and is the sole property of of Daily Political. If you are reading this piece of content on another domain, it was stolen and republished in violation of United States & international trademark & copyright law. The legal version of this piece of content can be read at https://www.dailypolitical.com/2017/09/23/benitec-biopharma-limited-bntc-upgraded-to-hold-at-valuengine.html.
About Benitec Biopharma Limited
Benitec Biopharma Limited is a biotechnology company. The Company is engaged in progressing programs through the clinic; the commercialization of its Intellectual Property (IP); development of its therapeutic pipeline and pre-clinical programs, and funding, and protecting and building the IP estate. Its In-house product candidates include TT-034, BB-HB-331, BB-AMD-211 and ddRNAi therapeutic.
Receive News & Ratings for Benitec Biopharma Limited Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Benitec Biopharma Limited and related companies with MarketBeat.com's FREE daily email newsletter.